Different Approaches to Pricing and Reimbursement of Innovative Pharmaceutical Products in Europe
Abstract
All aspects of the pharmaceutical market are heavily regulated due to the major public health implications related to the use of pharmaceutical products. Pricing and reimbursement of pharmaceutical products is the area posing the greatest level of challenge to pharmaceutical and biotech firms operating on a multinational basis. Each individual country is governed by its own pricing and reimbursement rules and procedures and - despite European legislation mandating transparency of decisions and harmonized timelines - the outcome of the various national pricing and reimbursement processes may vary dramatically both in terms of timing and results.
